• Product NameDCC-2036 (Rebastinib)
• Brief DescriptionInhibitors
• Purification99.53%
• Biological ActivityDCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.
• Target NameBcr-Abl inhibitor; FLT inhibitor
• CAS No. 1020172-07-9
• Calculated MW 553.59
• Formulation C30H28FN7O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular System
  SMILES:CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C3=CC4=C(C=C3)N=CC=C4)C(C)(C)C)C=C2)=C1
  Pathways:Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors
  Receptor:Abl1; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native); FLT3
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 16 mg/mL (28.9 mM); DMSO: 111 mg/mL (200.5 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Chan WW, et al. Y Cell. 2011, 19(4), 556-568.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting